secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-01-19T23:59:59+00:00
Accession:  0001140361-23-002126
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences terminates CSO Grant Blouse effective Jan 15, 2023
-----------------------------------------------------------------------

- Grant Blouse terminated as Chief Scientific Officer effective January 15, 2023.
- Severance per employment agreement plus bonus payments previously disclosed in Dec 27, 2022 8-K.
- Blouse will provide consulting services regarding potential sale or license of legacy hemophilia programs.
- Company retains Blouse's expertise while reducing executive headcount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123002126/0001140361-23-002126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123002126/brhc10046770_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-002126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer